<DOC>
	<DOCNO>NCT01956552</DOCNO>
	<brief_summary>The primary objective compare phenotype genotype primary tumor metastasis order optimize treatment metastatic disease , patient present first metastatic progression breast cancer .</brief_summary>
	<brief_title>Changes Phenotype Genotype Breast Cancers During Metastatic Process Optimization Therapeutic Targeting ( ESOPE )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>To eligible participate study , patient must fulfill follow criterion : Female patient . Age ≥ 18 year . ECOG performance status ≤ 2 . Metastatic breast carcinoma , either diagnosis first metastatic relapse . Available FFPE +/ frozen primary tumor sample . Evaluable metastatic disease . Metastatic disease outside previous radiotherapy field ( e.g . subclavicular internal mammary lymph node ) . Metastatic disease accessible either percutaneous surgical sampling . Signed write inform consent ( approved Independent Ethics Committee obtain prior studyspecific screen procedure ) . Social psychological welfare concordance compliance study . To eligible participate study , patient must fulfill none follow criterion : Bilateral multifocal breast cancer . Isolated local contralateral relapse . Solitary bone and/or brain metastatic disease unless : Metastatic site eligible therapeutic surgery . Metastatic site sample diagnosis purpose . Past current history malignant neoplasm , except curatively treat basal squamous cell carcinoma skin . Carcinoma situ cervix . Any coagulopathy contraindicating tumor biopsy . Presence contraindication general anesthesia , require .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Metastatic breast cancer</keyword>
	<keyword>Tumor biopsy</keyword>
	<keyword>Phenotype genotype characterization</keyword>
</DOC>